{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=DNA+vaccine+placebo&page=2", "query": { "intervention": "DNA vaccine placebo", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 68, "total_pages": 7, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=DNA+vaccine+placebo&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=DNA+vaccine+placebo&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-03T16:26:05.047Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00115960", "title": "Safety of and Immune Response to an HIV Preventive Vaccine (HIV-1 Gag DNA Alone or With IL-15 DNA) Given With or Without 2 Different Booster Vaccinations in HIV Uninfected Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "HIV-1 gag DNA", "type": "BIOLOGICAL" }, { "name": "IL-15 DNA adjuvant", "type": "BIOLOGICAL" }, { "name": "IL-12 DNA adjuvant", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 120, "start_date": null, "completion_date": "2008-07", "has_results": false, "last_update_posted_date": "2021-10-14", "last_synced_at": "2026-10-03T16:26:05.047Z", "location_count": 6, "location_summary": "Boston, Massachusetts • New York, New York • Rochester, New York + 2 more", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "Rochester", "state": "New York" }, { "city": "The Bronx", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00115960" }, { "nct_id": "NCT03606213", "title": "Therapeutic Vaccination in Treated HIV Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "HIV-1-infection" ], "interventions": [ { "name": "PENNVAX-GP", "type": "BIOLOGICAL" }, { "name": "INO-6145", "type": "BIOLOGICAL" }, { "name": "INO-9012", "type": "BIOLOGICAL" }, { "name": "CELLECTRA® 2000", "type": "DEVICE" } ], "intervention_types": [ "BIOLOGICAL", "DEVICE" ], "sponsor": "Steven Deeks", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 56, "start_date": "2018-08-01", "completion_date": "2021-05-17", "has_results": true, "last_update_posted_date": "2023-05-31", "last_synced_at": "2026-10-03T16:26:05.047Z", "location_count": 2, "location_summary": "Los Angeles, California • San Francisco, California", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03606213" }, { "nct_id": "NCT03560258", "title": "HIV-1-Gag Conserved-Element DNA Vaccine (p24CE) Vaccine Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "p24CE1/2 pDNA vaccine", "type": "BIOLOGICAL" }, { "name": "p24CE1/2 pDNA vaccine admixed with full-length p55^gag pDNA vaccine", "type": "BIOLOGICAL" }, { "name": "Full-length p55^gag pDNA vaccine", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 45, "start_date": "2019-03-26", "completion_date": "2021-02-10", "has_results": true, "last_update_posted_date": "2022-04-26", "last_synced_at": "2026-10-03T16:26:05.047Z", "location_count": 14, "location_summary": "Birmingham, Alabama • Los Angeles, California • San Francisco, California + 9 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT03560258" }, { "nct_id": "NCT01571960", "title": "Evaluating the Safety and Immune Response of a Prime-Boost HIV Vaccine Regimen in Healthy, HIV-Uninfected, Vaccinia-Naive Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "GEO-D03 DNA vaccine", "type": "BIOLOGICAL" }, { "name": "MVA/HIV62B (MVA62B) vaccine", "type": "BIOLOGICAL" }, { "name": "Placebo for GEO-D03 DNA", "type": "BIOLOGICAL" }, { "name": "Placebo for MVA62B:", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 48, "start_date": "2012-04", "completion_date": "2016-01", "has_results": false, "last_update_posted_date": "2021-10-15", "last_synced_at": "2026-10-03T16:26:05.047Z", "location_count": 4, "location_summary": "Birmingham, Alabama • San Francisco, California • Boston, Massachusetts + 1 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "San Francisco", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Rochester", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01571960" }, { "nct_id": "NCT01578889", "title": "Evaluating the Safety of and Immune Response to HIV-MAG DNA Vaccine With or Without Plasmid IL-12 Adjuvant Delivered Intramuscularly Via Electroporation Followed by VSV-gag HIV Vaccine Boost in Healthy, HIV-Uninfected Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "HIV-MAG vaccine", "type": "BIOLOGICAL" }, { "name": "IL-12 pDNA adjuvant", "type": "BIOLOGICAL" }, { "name": "VSV HIV gag vaccine", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" }, { "name": "Ichor Medical Systems TriGrid™ Delivery System (TDS) electroporation (EP) device", "type": "DEVICE" } ], "intervention_types": [ "BIOLOGICAL", "DEVICE" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 100, "start_date": "2012-05", "completion_date": "2016-10", "has_results": false, "last_update_posted_date": "2021-10-15", "last_synced_at": "2026-10-03T16:26:05.047Z", "location_count": 5, "location_summary": "New York, New York • Rochester, New York • Philadelphia, Pennsylvania + 1 more", "locations": [ { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "Rochester", "state": "New York" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT01578889" }, { "nct_id": "NCT02852005", "title": "Evaluating the Immunogenicity of the AIDSVAX B/E Vaccine and the MVA/HIV62B Vaccine in Healthy, HIV-1-Uninfected Adults Who Previously Received MVA/HIV62B in DNA/MVA or MVA/MVA Regimens in HVTN 205", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "MVA/HIV62B vaccine", "type": "BIOLOGICAL" }, { "name": "AIDSVAX B/E vaccine", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 27, "start_date": "2017-01", "completion_date": "2019-10-29", "has_results": true, "last_update_posted_date": "2022-08-08", "last_synced_at": "2026-10-03T16:26:05.047Z", "location_count": 7, "location_summary": "Birmingham, Alabama • San Francisco, California • Decatur, Georgia + 4 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "San Francisco", "state": "California" }, { "city": "Decatur", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02852005" }, { "nct_id": "NCT03181789", "title": "Safety and Immunogenicity of pDNA Vaccines Expressing HIV M Group p24^Gag Conserved Elements and/or p55^Gag, Administered With IL-12 pDNA", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "p24CE1/2 pDNA Vaccine", "type": "BIOLOGICAL" }, { "name": "p55^gag pDNA Vaccine", "type": "BIOLOGICAL" }, { "name": "IL-12 pDNA Adjuvant", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" }, { "name": "Ichor Medical Systems Intramuscular TriGrid Delivery System (TDS-IM) electroporation (EP) device", "type": "DEVICE" } ], "intervention_types": [ "BIOLOGICAL", "DEVICE" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 56, "start_date": "2017-10-18", "completion_date": "2020-04-29", "has_results": true, "last_update_posted_date": "2024-02-07", "last_synced_at": "2026-10-03T16:26:05.047Z", "location_count": 3, "location_summary": "San Francisco, California • Decatur, Georgia • Cleveland, Ohio", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Decatur", "state": "Georgia" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT03181789" }, { "nct_id": "NCT02654080", "title": "Evaluating the Safety, Tolerability, and Immunogenicity of a Prime-Boost Regimen of HIV-1 Nef/Tat/Vif, Env pDNA Vaccine Delivered Intramuscularly With Electroporation and HIV-1 rVSV envC Vaccine in Healthy, HIV-Uninfected Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "HIV-1 nef/tat/vif, env pDNA vaccine", "type": "BIOLOGICAL" }, { "name": "rVSV HIV envC vaccine", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 14, "start_date": "2016-03", "completion_date": "2019-07-01", "has_results": false, "last_update_posted_date": "2021-10-15", "last_synced_at": "2026-10-03T16:26:05.047Z", "location_count": 2, "location_summary": "Cleveland, Ohio • Philadelphia, Pennsylvania", "locations": [ { "city": "Cleveland", "state": "Ohio" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02654080" }, { "nct_id": "NCT02915016", "title": "Evaluating the Safety and Immunogenicity of HIV Clade C DNA Vaccine and MF59- or AS01B-Adjuvanted Clade C Env Protein Vaccines in Various Combinations in Healthy, HIV-Uninfected Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "DNA-HIV-PT123 vaccine", "type": "BIOLOGICAL" }, { "name": "Bivalent Subtype C gp120/MF59 vaccine", "type": "BIOLOGICAL" }, { "name": "Bivalent Subtype C gp120/AS01B vaccine", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "40 Years", "sex": "ALL", "summary": "18 Years to 40 Years" }, "enrollment_count": 334, "start_date": "2016-12-07", "completion_date": "2020-02-12", "has_results": true, "last_update_posted_date": "2022-04-29", "last_synced_at": "2026-10-03T16:26:05.047Z", "location_count": 8, "location_summary": "Birmingham, Alabama • Boston, Massachusetts • New York, New York + 3 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02915016" }, { "nct_id": "NCT02030301", "title": "Safety and Efficacy Trial of DNA Vaccines to Treat Genital Herpes in Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Genital Herpes Simplex Type 2" ], "interventions": [ { "name": "VCL-HB01", "type": "BIOLOGICAL" }, { "name": "VCL-HM01", "type": "BIOLOGICAL" }, { "name": "PBS", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Vical", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 165, "start_date": "2013-12", "completion_date": "2016-02", "has_results": false, "last_update_posted_date": "2019-02-27", "last_synced_at": "2026-10-03T16:26:05.047Z", "location_count": 7, "location_summary": "Birmingham, Alabama • Hollywood, Florida • Indianapolis, Indiana + 4 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Hollywood", "state": "Florida" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Portland", "state": "Oregon" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02030301" } ] }